Your browser doesn't support javascript.
loading
Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.
Hochster, H S; Uboha, N; Messersmith, W; Gold, P J; ONeil, B H; Cohen, D; Denlinger, C; Cohen, S; Leichman, C G; Leichman, L; Lenz, H-J.
Affiliation
  • Hochster HS; Yale Cancer Center, 333 Cedar Street, New Haven, CT, 06520, USA, howard.hochster@yale.edu.
Cancer Chemother Pharmacol ; 75(1): 17-23, 2015 Jan.
Article in En | MEDLINE | ID: mdl-25322874

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Benzimidazoles / Camptothecin / Colorectal Neoplasms / Antineoplastic Combined Chemotherapy Protocols / MAP Kinase Kinase Kinases / Protein Kinase Inhibitors / Topoisomerase I Inhibitors Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies Language: En Journal: Cancer Chemother Pharmacol Year: 2015 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Benzimidazoles / Camptothecin / Colorectal Neoplasms / Antineoplastic Combined Chemotherapy Protocols / MAP Kinase Kinase Kinases / Protein Kinase Inhibitors / Topoisomerase I Inhibitors Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies Language: En Journal: Cancer Chemother Pharmacol Year: 2015 Type: Article